Herein, we investigated the efficacy and safety of the V‐HAG regimen (VEN, HHT, cytarabine, and granulocyte colony‐stimulating factor [G‐CSF]) in patients with refractory/relapsed ETP‐ALL through a prospective, multicenter, single‐arm, open‐label, phase 2 clinical trial. This evidence concerns the gene CSF3 and acute lymphoblastic leukemia.